{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T06:02:27Z","timestamp":1785564147561,"version":"3.56.0"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s10555-024-10228-0","type":"journal-article","created":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T18:35:21Z","timestamp":1733078121000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms"],"prefix":"10.1007","volume":"44","author":[{"given":"Tyce J.","family":"Kearl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fateeha","family":"Furqan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirav N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,1]]},"reference":[{"issue":"11","key":"10228_CR1","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.3390\/jpm13111595","volume":"13","author":"M Ostojska","year":"2023","unstructured":"Ostojska, M., Nowak, E., Twardowska, J., Lejman, M., & Zawitkowska, J. (2023). CAR-T cell therapy in the treatment of pediatric non-Hodgkin lymphoma. Journal of Personalized Medicine, 13(11), 1595. https:\/\/doi.org\/10.3390\/jpm13111595","journal-title":"Journal of Personalized Medicine"},{"key":"10228_CR2","doi-asserted-by":"publisher","unstructured":"Blasi, R. D., Gouill, S. L., Bachy, E., Cartron, G., Beauvais, D., Bras, F. L., \u2026 Thieblemont, C. (2022). Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: A DESCAR-T analysis. Blood, 140(24), 2584\u20132593. https:\/\/doi.org\/10.1182\/blood.2022016945","DOI":"10.1182\/blood.2022016945"},{"key":"10228_CR3","unstructured":"Novartis Pharmaceuticals Corp. (2022). KYMRIAH. [package insert]."},{"key":"10228_CR4","unstructured":"Bristol-Myers Squibb Company. (2023). BREYANZI. [package insert]."},{"key":"10228_CR5","unstructured":"Kite Pharma, Inc. (2023). YESCARTA. [package insert]."},{"key":"10228_CR6","unstructured":"Kite Pharma, Inc. (2023). TECARTUS. [package insert]."},{"key":"10228_CR7","doi-asserted-by":"publisher","unstructured":"Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., \u2026 Go, W. Y. (2017). Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New England Journal of Medicine, 377(26), 2531\u20132544. https:\/\/doi.org\/10.1056\/nejmoa1707447","DOI":"10.1056\/nejmoa1707447"},{"key":"10228_CR8","doi-asserted-by":"publisher","unstructured":"Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, \u00d6., \u2026 June, C. H. (2017). Chimeric antigen receptor T cells in refractory B-cell lymphomas. The New England Journal of Medicine, 377(26), 2545\u20132554. https:\/\/doi.org\/10.1056\/nejmoa1708566","DOI":"10.1056\/nejmoa1708566"},{"key":"10228_CR9","doi-asserted-by":"publisher","unstructured":"Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., \u2026 Investigators, J. (2018). Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. New England Journal of Medicine, 380(1), 45\u201356. https:\/\/doi.org\/10.1056\/nejmoa1804980","DOI":"10.1056\/nejmoa1804980"},{"key":"10228_CR10","doi-asserted-by":"publisher","unstructured":"Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M., Arnason, J., \u2026 Siddiqi, T. (2020). Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study. The Lancet, 396(10254), 839\u2013852. https:\/\/doi.org\/10.1016\/s0140-6736(20)31366-0","DOI":"10.1016\/s0140-6736(20)31366-0"},{"key":"10228_CR11","doi-asserted-by":"publisher","unstructured":"Jacobson, C. A., Chavez, J. C., Sehgal, A. R., William, B. M., Munoz, J., Salles, G., \u2026 Neelapu, S. S. (2022). Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial. The Lancet Oncology, 23(1), 91\u2013103. https:\/\/doi.org\/10.1016\/s1470-2045(21)00591-x","DOI":"10.1016\/s1470-2045(21)00591-x"},{"key":"10228_CR12","doi-asserted-by":"publisher","unstructured":"Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., \u2026 Reagan, P. M. (2020). KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. New England Journal of Medicine, 382(14), 1331\u20131342. https:\/\/doi.org\/10.1056\/nejmoa1914347","DOI":"10.1056\/nejmoa1914347"},{"key":"10228_CR13","doi-asserted-by":"publisher","unstructured":"Locke, F. L., Siddiqi, T., Jacobson, C. A., Ghobadi, A., Ahmed, S., Miklos, D. B., \u2026 Pasquini, M. C. (2022). Real-world outcomes of axicabtagene ciloleucel (axi-cel) for the treatment of large B-cell lymphoma (LBCL) by race and ethnicity. Journal of Clinical Oncology, 40(16_suppl), 7571\u20137571. https:\/\/doi.org\/10.1200\/jco.2022.40.16_suppl.7571","DOI":"10.1200\/jco.2022.40.16_suppl.7571"},{"key":"10228_CR14","doi-asserted-by":"publisher","unstructured":"Jacobson, C. A., Munoz, J., Sun, F., Kanters, S., Limbrick-Oldfield, E. H., Spooner, C., \u2026 Dickinson, M. (2024). Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: A systematic review and meta-analysis. Transplantation and Cellular Therapy, 30(1), 77.e1\u201377.e15. https:\/\/doi.org\/10.1016\/j.jtct.2023.10.017","DOI":"10.1016\/j.jtct.2023.10.017"},{"key":"10228_CR15","doi-asserted-by":"publisher","unstructured":"Locke, F. L., Miklos, D. B., Jacobson, C. A., Perales, M.-A., Kersten, M.-J., Oluwole, O. O., \u2026 Westin, J. R. (2022). Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. New England Journal of Medicine, 386(7), 640\u2013654. https:\/\/doi.org\/10.1056\/nejmoa2116133","DOI":"10.1056\/nejmoa2116133"},{"key":"10228_CR16","doi-asserted-by":"publisher","unstructured":"Bishop, M. R., Dickinson, M., Purtill, D., Barba, P., Santoro, A., Hamad, N., \u2026 Westin, J. R. (2022). Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. New England Journal of Medicine, 386(7), 629\u2013639. https:\/\/doi.org\/10.1056\/nejmoa2116596","DOI":"10.1056\/nejmoa2116596"},{"key":"10228_CR17","doi-asserted-by":"publisher","unstructured":"Kamdar, M., Solomon, S. R., Arnason, J., Johnston, P. B., Glass, B., Bachanova, V., \u2026 Investigators, T. (2022). Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): Results from an interim analysis of an open-label, randomised, phase 3 trial. The Lancet, 399(10343), 2294\u20132308. https:\/\/doi.org\/10.1016\/s0140-6736(22)00662-6","DOI":"10.1016\/s0140-6736(22)00662-6"},{"key":"10228_CR18","doi-asserted-by":"publisher","unstructured":"Westin, J. R., Oluwole, O. O., Kersten, M. J., Miklos, D. B., Perales, M.-A., Ghobadi, A., \u2026 Members, K. (2023). Survival with axicabtagene ciloleucel in large B-cell lymphoma. New England Journal of Medicine, 389(2), 148\u2013157. https:\/\/doi.org\/10.1056\/nejmoa2301665","DOI":"10.1056\/nejmoa2301665"},{"key":"10228_CR19","doi-asserted-by":"publisher","unstructured":"Neelapu, S. S., Dickinson, M., Munoz, J., Ulrickson, M. L., Thieblemont, C., Oluwole, O. O., \u2026 Chavez, J. C. (2022). Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: The phase 2 ZUMA-12 trial. Nature Medicine, 28(4), 735\u2013742. https:\/\/doi.org\/10.1038\/s41591-022-01731-4","DOI":"10.1038\/s41591-022-01731-4"},{"key":"10228_CR20","doi-asserted-by":"publisher","unstructured":"Chavez, J. C., Dickinson, M., Munoz, J. L., Ulrickson, M. L., Thieblemont, C., Oluwole, O. O., \u2026 Neelapu, S. S. (2023). 3-year analysis of ZUMA-12: A phase 2 study of axicabtagene ciloleucel (axi-cel) as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL). Blood, 142(Supplement 1), 894. https:\/\/doi.org\/10.1182\/blood-2023-174510","DOI":"10.1182\/blood-2023-174510"},{"key":"10228_CR21","doi-asserted-by":"publisher","unstructured":"Sharon, T. D., Assayag, M., Avni, B., Kfir\u2010Erenfeld, S., Lebel, E., Gatt, M. E., \u2026 Grisariu, S. (2023). Early lymphocyte collection for anti\u2010CD19 CART production improves T\u2010cell fitness in patients with relapsed\/refractory diffuse large B\u2010cell lymphoma. British Journal of Haematology, 202(1), 74\u201385. https:\/\/doi.org\/10.1111\/bjh.18816","DOI":"10.1111\/bjh.18816"},{"key":"10228_CR22","doi-asserted-by":"publisher","unstructured":"Locke, F. L., Lekakis, L. J., Eradat, H., Munoz, J., Tees, M. T., Vos, S. de, \u2026 Neelapu, S. S. (2023). Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501\/501A in relapsed\/refractory large B-cell lymphoma (r\/r LBCL). Journal of Clinical Oncology, 41(16_suppl), 2517\u20132517. https:\/\/doi.org\/10.1200\/jco.2023.41.16_suppl.2517","DOI":"10.1200\/jco.2023.41.16_suppl.2517"},{"key":"10228_CR23","doi-asserted-by":"publisher","unstructured":"Zurko, J. C., Xu, H., Chaney, K., Fenske, T. S., Hamadani, M., Schneider, D., \u2026 Shah, N. N. (2021). Bispecific LV20.19 CAR T-cells expanded in IL-7 and IL-15 have greater polyfunctionality and polyfunctional strength than CAR T-cells expanded in IL-2. Blood, 138(Supplement 1), 1728\u20131728. https:\/\/doi.org\/10.1182\/blood-2021-146882","DOI":"10.1182\/blood-2021-146882"},{"key":"10228_CR24","doi-asserted-by":"publisher","unstructured":"Xu, Y., Zhang, M., Ramos, C. A., Durett, A., Liu, E., Dakhova, O., \u2026 Dotti, G. (2014). Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood, 123(24), 3750\u20133759. https:\/\/doi.org\/10.1182\/blood-2014-01-552174","DOI":"10.1182\/blood-2014-01-552174"},{"key":"10228_CR25","doi-asserted-by":"publisher","unstructured":"Ghassemi, S., Nunez-Cruz, S., O\u2019Connor, R. S., Fraietta, J. A., Patel, P. R., Scholler, J., \u2026 Milone, M. C. (2018). Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells. Cancer Immunology Research, 6(9), 1100\u20131109. https:\/\/doi.org\/10.1158\/2326-6066.cir-17-0405","DOI":"10.1158\/2326-6066.cir-17-0405"},{"key":"10228_CR26","doi-asserted-by":"publisher","unstructured":"Michelozzi, I. M., Gomez-Castaneda, E., Pohle, R. V. C., Rodriguez, F. C., Sufi, J., Costa, P. P., \u2026 Giustacchini, A. (2023). Activation priming and cytokine polyfunctionality modulate the enhanced functionality of low-affinity CD19 CAR T cells. Blood Advances, 7(9), 1725\u20131738. https:\/\/doi.org\/10.1182\/bloodadvances.2022008490","DOI":"10.1182\/bloodadvances.2022008490"},{"key":"10228_CR27","doi-asserted-by":"publisher","unstructured":"Urak, R., Walter, M., Lim, L., Wong, C. W., Budde, L. E., Thomas, S., \u2026 Wang, X. (2017). Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy. Journal for ImmunoTherapy of Cancer, 5(1), 26. https:\/\/doi.org\/10.1186\/s40425-017-0227-4","DOI":"10.1186\/s40425-017-0227-4"},{"key":"10228_CR28","doi-asserted-by":"publisher","unstructured":"Kong, W., Dimitri, A., Wang, W., Jung, I.-Y., Ott, C. J., Fasolino, M., \u2026 Fraietta, J. A. (2021). BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. Journal of Clinical Investigation, 131(16), e145459. https:\/\/doi.org\/10.1172\/jci145459","DOI":"10.1172\/jci145459"},{"key":"10228_CR29","doi-asserted-by":"publisher","unstructured":"Roddie, C., Lekakis, L. J., Marzolini, M. A. V., Ramakrishnan, A., Zhang, Y., Hu, Y., \u2026 Pule, M. (2023). Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed\/refractory large B cell lymphoma. Blood, 141(20), 2470\u20132482. https:\/\/doi.org\/10.1182\/blood.2022018598","DOI":"10.1182\/blood.2022018598"},{"key":"10228_CR30","doi-asserted-by":"publisher","unstructured":"Shah, N. N., Johnson, B. D., Schneider, D., Zhu, F., Szabo, A., Keever-Taylor, C. A., \u2026 Hari, P. (2020). Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: A phase 1 dose escalation and expansion trial. Nat Med, 26(10), 1569\u20131575. https:\/\/doi.org\/10.1038\/s41591-020-1081-3","DOI":"10.1038\/s41591-020-1081-3"},{"key":"10228_CR31","doi-asserted-by":"publisher","unstructured":"Qu, C., Zou, R., Wang, P., Zhu, Q., Kang, L., Ping, N., \u2026 Jin, Z. (2022). Decitabine-primed tandem CD19\/CD22 CAR-T therapy in relapsed\/refractory diffuse large B-cell lymphoma patients. Frontiers in Immunology, 13, 969660. https:\/\/doi.org\/10.3389\/fimmu.2022.969660","DOI":"10.3389\/fimmu.2022.969660"},{"issue":"Supplement 1","key":"10228_CR32","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1182\/blood-2023-189733","volume":"142","author":"MJ Cortese","year":"2023","unstructured":"Cortese, M. J., Mavis, C., Mandeville, T. K., Gu, J., Bowman, K., & Hernandez-Ilizaliturri, F. J. (2023). Venetoclax pre-treatment of CLL\/SLL patients enhances autologous CAR T-Cells Efficacy. Blood, 142(Supplement 1), 6518. https:\/\/doi.org\/10.1182\/blood-2023-189733","journal-title":"Blood"},{"key":"10228_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.molimm.2020.01.006","volume":"119","author":"Y Otsuka","year":"2020","unstructured":"Otsuka, Y., Nishikori, M., Arima, H., Izumi, K., Kitawaki, T., Hishizawa, M., & Takaori-Kondo, A. (2020). EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas. Molecular Immunology, 119, 35\u201345. https:\/\/doi.org\/10.1016\/j.molimm.2020.01.006","journal-title":"Molecular Immunology"},{"issue":"9","key":"10228_CR34","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.3109\/10428194.2015.1011640","volume":"56","author":"Z-Z Yang","year":"2015","unstructured":"Yang, Z.-Z., Liang, A.-B., & Ansell, S. M. (2015). T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: Activation, suppression and exhaustion. Leukemia & Lymphoma, 56(9), 2498\u20132504. https:\/\/doi.org\/10.3109\/10428194.2015.1011640","journal-title":"Leukemia & Lymphoma"},{"key":"10228_CR35","doi-asserted-by":"publisher","unstructured":"Dorfman, D. M., Schultze, J. L., Shahsafaei, A., Michalak, S., Gribben, J. G., Freeman, G. J., \u2026 Nadler, L. M. (1997). In vivo expression of B7\u20131 and B7\u20132 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood, 90(11), 4297\u20134306. https:\/\/doi.org\/10.1182\/blood.v90.11.4297","DOI":"10.1182\/blood.v90.11.4297"},{"issue":"Supplement_1","key":"10228_CR36","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1182\/blood-2019-126217","volume":"134","author":"A Greenbaum","year":"2019","unstructured":"Greenbaum, A., Gopal, A. K., Fromm, J. R., & Houghton, A. M. (2019). Diffuse large B-cell lymphoma is infiltrated with functional CD8+ T-cells lacking the hallmarks of exhaustion. Blood, 134(Supplement_1), 1518. https:\/\/doi.org\/10.1182\/blood-2019-126217","journal-title":"Blood"},{"key":"10228_CR37","doi-asserted-by":"publisher","unstructured":"Yang, Z.-Z., Grote, D. M., Ziesmer, S. C., Niki, T., Hirashima, M., Novak, A. J., \u2026 Ansell, S. M. (2012). IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. Journal of Clinical Investigation, 122(4), 1271\u20131282. https:\/\/doi.org\/10.1172\/jci59806","DOI":"10.1172\/jci59806"},{"key":"10228_CR38","doi-asserted-by":"publisher","unstructured":"Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., \u2026 Melenhorst, J. J. (2018). Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nature Medicine, 24(5), 563\u2013571. https:\/\/doi.org\/10.1038\/s41591-018-0010-1","DOI":"10.1038\/s41591-018-0010-1"},{"key":"10228_CR39","doi-asserted-by":"publisher","unstructured":"Filosto, S., Vardhanabhuti, S., Canales, M. A., Poire, X., Lekakis, L. J., Vos, S. de, \u2026 Westin, J. R. (2023). Product attributes of CAR T-cell therapy differentially associate with efficacy and toxicity in second-line large B-cell lymphoma (ZUMA-7). Blood Cancer Discovery, 5(1), 21\u201333. https:\/\/doi.org\/10.1158\/2643-3230.bcd-23-0112","DOI":"10.1158\/2643-3230.bcd-23-0112"},{"key":"10228_CR40","doi-asserted-by":"publisher","unstructured":"Fraietta, J. A., Nobles, C. L., Sammons, M. A., Lundh, S., Carty, S. A., Reich, T. J., \u2026 Melenhorst, J. J. (2018). Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature, 558(7709), 307\u2013312. https:\/\/doi.org\/10.1038\/s41586-018-0178-z","DOI":"10.1038\/s41586-018-0178-z"},{"key":"10228_CR41","doi-asserted-by":"publisher","unstructured":"Jain, N., Zhao, Z., Feucht, J., Koche, R., Iyer, A., Dobrin, A., \u2026 Sadelain, M. (2023). TET2 guards against unchecked BATF3-induced CAR T cell expansion. Nature, 615(7951), 315\u2013322. https:\/\/doi.org\/10.1038\/s41586-022-05692-z","DOI":"10.1038\/s41586-022-05692-z"},{"key":"10228_CR42","doi-asserted-by":"publisher","unstructured":"Wang, J., Hasan, F., Frey, A. C., Li, H. S., Park, J., Pan, K., \u2026 Yee, C. (2020). Histone deacetylase inhibitors and IL21 cooperate to reprogram human effector CD8+ T cells to memory T cells. Cancer Immunology Research, 8(6), 794\u2013805. https:\/\/doi.org\/10.1158\/2326-6066.cir-19-0619","DOI":"10.1158\/2326-6066.cir-19-0619"},{"key":"10228_CR43","doi-asserted-by":"publisher","unstructured":"Shen, C., Li, M., Duan, Y., Jiang, X., Hou, X., Xue, F., \u2026 Luo, Y. (2023). HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma. Frontiers in Immunology, 14, 1170207. https:\/\/doi.org\/10.3389\/fimmu.2023.1170207","DOI":"10.3389\/fimmu.2023.1170207"},{"key":"10228_CR44","doi-asserted-by":"publisher","unstructured":"Lei, X., Ou, Z., Yang, Z., Zhong, J., Zhu, Y., Tian, J., \u2026 Fan, S. (2021). A pan-histone deacetylase inhibitor enhances the antitumor activity of B7-H3\u2013specific CAR T cells in solid tumors. Clinical Cancer Research, 27(13), 3757\u20133771. https:\/\/doi.org\/10.1158\/1078-0432.ccr-20-2487","DOI":"10.1158\/1078-0432.ccr-20-2487"},{"key":"10228_CR45","doi-asserted-by":"publisher","unstructured":"Funk, C. R., Wang, S., Chen, K. Z., Waller, A., Sharma, A., Edgar, C. L., \u2026 Waller, E. K. (2022). PI3K\u03b4\/\u03b3 inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity. Blood, 139(4), 523\u2013537. https:\/\/doi.org\/10.1182\/blood.2021011597","DOI":"10.1182\/blood.2021011597"},{"key":"10228_CR46","doi-asserted-by":"publisher","unstructured":"Collins, M. A., Jung, I.-Y., Zhao, Z., Apodaca, K., Kong, W., Lundh, S., \u2026 Melenhorst, J. J. (2022). Enhanced co-stimulatory signaling improves CAR T cell effector responses in CLL. Cancer Research Communications, 2(9), 1089\u20131103. https:\/\/doi.org\/10.1158\/2767-9764.crc-22-0200","DOI":"10.1158\/2767-9764.crc-22-0200"},{"issue":"3","key":"10228_CR47","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s12032-022-01913-7","volume":"40","author":"X Zhu","year":"2023","unstructured":"Zhu, X., Li, W., Gao, J., Shen, J., Xu, Y., Zhang, C., & Qian, C. (2023). RUNX3 improves CAR-T cell phenotype and reduces cytokine release while maintaining CAR-T function. Medical Oncology, 40(3), 89. https:\/\/doi.org\/10.1007\/s12032-022-01913-7","journal-title":"Medical Oncology"},{"key":"10228_CR48","doi-asserted-by":"publisher","unstructured":"Trefny, M. P., Kirchhammer, N., Maur, P. A. der, Natoli, M., Schmid, D., Germann, M., \u2026 Zippelius, A. (2023). Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy. Nature Communications, 14(1), 86. https:\/\/doi.org\/10.1038\/s41467-022-35583-w","DOI":"10.1038\/s41467-022-35583-w"},{"key":"10228_CR49","doi-asserted-by":"publisher","unstructured":"Ando, M., Kondo, T., Tomisato, W., Ito, M., Shichino, S., Srirat, T., \u2026 Yoshimura, A. (2021). Rejuvenating effector\/exhausted CAR T cells to stem cell memory\u2013like CAR T cells by resting them in the presence of CXCL12 and the NOTCH ligandstem cell memory\u2013like CAR T cells by CXCL12 and NOTCH. Cancer Research Communications, 1(1), 41\u201355. https:\/\/doi.org\/10.1158\/2767-9764.crc-21-0034","DOI":"10.1158\/2767-9764.crc-21-0034"},{"key":"10228_CR50","doi-asserted-by":"publisher","unstructured":"Jung, I.-Y., Narayan, V., McDonald, S., Rech, A. J., Bartoszek, R., Hong, G., \u2026 Fraietta, J. A. (2022). BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion. Science Translational Medicine, 14(670), eabn7336\u2013eabn7336. https:\/\/doi.org\/10.1126\/scitranslmed.abn7336","DOI":"10.1126\/scitranslmed.abn7336"},{"key":"10228_CR51","doi-asserted-by":"publisher","unstructured":"Lynn, R. C., Weber, E. W., Sotillo, E., Gennert, D., Xu, P., Good, Z., \u2026 Mackall, C. L. (2019). c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature, 576(7786), 293\u2013300. https:\/\/doi.org\/10.1038\/s41586-019-1805-z","DOI":"10.1038\/s41586-019-1805-z"},{"key":"10228_CR52","doi-asserted-by":"publisher","unstructured":"Weber, E. W., Parker, K. R., Sotillo, E., Lynn, R. C., Anbunathan, H., Lattin, J., \u2026 Mackall, C. L. (2021). Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science, 372(6537), eaba1786. https:\/\/doi.org\/10.1126\/science.aba1786","DOI":"10.1126\/science.aba1786"},{"key":"10228_CR53","doi-asserted-by":"publisher","unstructured":"Mestermann, K., Giavridis, T., Weber, J., Rydzek, J., Frenz, S., Nerreter, T., \u2026 Hudecek, M. (2019). The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells. Science Translational Medicine, 11(499). https:\/\/doi.org\/10.1126\/scitranslmed.aau5907","DOI":"10.1126\/scitranslmed.aau5907"},{"key":"10228_CR54","doi-asserted-by":"publisher","unstructured":"Eyquem, J., Mansilla-Soto, J., Giavridis, T., Stegen, S. J. C. van der, Hamieh, M., Cunanan, K. M., \u2026 Sadelain, M. (2017). Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature, 543(7643), 113\u2013117. https:\/\/doi.org\/10.1038\/nature21405","DOI":"10.1038\/nature21405"},{"issue":"2","key":"10228_CR55","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/leu.2015.247","volume":"30","author":"D Sommermeyer","year":"2016","unstructured":"Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2016). Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia, 30(2), 492\u2013500. https:\/\/doi.org\/10.1038\/leu.2015.247","journal-title":"Leukemia"},{"key":"10228_CR56","doi-asserted-by":"publisher","unstructured":"Arcangeli, S., Bove, C., Mezzanotte, C., Camisa, B., Falcone, L., Manfredi, F., \u2026 Casucci, M. (2022). CAR T-cell manufacturing from naive\/stem memory T-lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. Journal of Clinical Investigation, 132(12), e150807. https:\/\/doi.org\/10.1172\/jci150807","DOI":"10.1172\/jci150807"},{"issue":"320","key":"10228_CR57","doi-asserted-by":"publisher","first-page":"320ra3","DOI":"10.1126\/scitranslmed.aad5222","volume":"8","author":"N Singh","year":"2016","unstructured":"Singh, N., Perazzelli, J., Grupp, S. A., & Barrett, D. M. (2016). Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Science Translational Medicine, 8(320), 320ra3. https:\/\/doi.org\/10.1126\/scitranslmed.aad5222","journal-title":"Science Translational Medicine"},{"key":"10228_CR58","doi-asserted-by":"publisher","unstructured":"Locke, F. L., Rossi, J. M., Neelapu, S. S., Jacobson, C. A., Miklos, D. B., Ghobadi, A., \u2026 Bot, A. (2020). Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances, 4(19), 4898\u20134911. https:\/\/doi.org\/10.1182\/bloodadvances.2020002394","DOI":"10.1182\/bloodadvances.2020002394"},{"key":"10228_CR59","doi-asserted-by":"publisher","unstructured":"Locke, F. L., Filosto, S., Chou, J., Vardhanabhuti, S., Perbost, R., Dreger, P., \u2026 Galon, J. (2024). Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma. Nature Medicine, 1\u201312. https:\/\/doi.org\/10.1038\/s41591-023-02754-1","DOI":"10.1038\/s41591-023-02754-1"},{"key":"10228_CR60","doi-asserted-by":"publisher","unstructured":"Deng, Q., Han, G., Puebla-Osorio, N., Ma, M. C. J., Strati, P., Chasen, B., \u2026 Green, M. R. (2020). Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nature Medicine, 1\u201310. https:\/\/doi.org\/10.1038\/s41591-020-1061-7","DOI":"10.1038\/s41591-020-1061-7"},{"key":"10228_CR61","doi-asserted-by":"publisher","unstructured":"Wang, Y., Tong, C., Lu, Y., Wu, Z., Guo, Y., Liu, Y., \u2026 Han, W. (2023). Characteristics of premanufacture CD8+ T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma. Signal Transduction and Targeted Therapy, 8(1), 409. https:\/\/doi.org\/10.1038\/s41392-023-01659-2","DOI":"10.1038\/s41392-023-01659-2"},{"key":"10228_CR62","doi-asserted-by":"publisher","unstructured":"Monfrini, C., Stella, F., Aragona, V., Magni, M., Ljevar, S., Vella, C., \u2026 Carniti, C. (2022). Phenotypic composition of commercial anti-CD19 CAR-T cells affects in vivo expansion and disease response in large B-cell lymphoma patients. Clinical Cancer Research, 28(15), 3378\u20133386. https:\/\/doi.org\/10.1158\/1078-0432.ccr-22-0164","DOI":"10.1158\/1078-0432.ccr-22-0164"},{"key":"10228_CR63","doi-asserted-by":"publisher","unstructured":"Haradhvala, N. J., Leick, M. B., Maurer, K., Gohil, S. H., Larson, R. C., Yao, N., \u2026 Maus, M. V. (2022). Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nature Medicine, 28(9), 1848\u20131859. https:\/\/doi.org\/10.1038\/s41591-022-01959-0","DOI":"10.1038\/s41591-022-01959-0"},{"key":"10228_CR64","doi-asserted-by":"publisher","unstructured":"Jackson, Z., Hong, C., Schauner, R., Dropulic, B., Caimi, P. F., Lima, M. de, \u2026 Wald, D. N. (2022). Sequential single-cell transcriptional and protein marker profiling reveals TIGIT as a marker of CD19 CAR-T cell dysfunction in patients with non-Hodgkin lymphoma. Cancer Discovery, 12(8), 1886\u20131903. https:\/\/doi.org\/10.1158\/2159-8290.cd-21-1586","DOI":"10.1158\/2159-8290.cd-21-1586"},{"key":"10228_CR65","doi-asserted-by":"publisher","unstructured":"Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., \u2026 Maloney, D. G. (2016). Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor\u2013modified T cells. Science Translational Medicine, 8(355), 355ra116. https:\/\/doi.org\/10.1126\/scitranslmed.aaf8621","DOI":"10.1126\/scitranslmed.aaf8621"},{"issue":"2","key":"10228_CR66","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s11864-021-00920-6","volume":"23","author":"A Khurana","year":"2022","unstructured":"Khurana, A., & Lin, Y. (2022). Allogeneic chimeric antigen receptor therapy in lymphoma. Current Treatment Options in Oncology, 23(2), 171\u2013187. https:\/\/doi.org\/10.1007\/s11864-021-00920-6","journal-title":"Current Treatment Options in Oncology"},{"key":"10228_CR67","doi-asserted-by":"publisher","unstructured":"Cieri, N., Camisa, B., Cocchiarella, F., Forcato, M., Oliveira, G., Provasi, E., \u2026 Bonini, C. (2013). IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood, 121(4), 573\u2013584. https:\/\/doi.org\/10.1182\/blood-2012-05-431718","DOI":"10.1182\/blood-2012-05-431718"},{"key":"10228_CR68","doi-asserted-by":"publisher","unstructured":"Gomez-Eerland, R., Nuijen, B., Heemskerk, B., Rooij, N. van, Berg, J. H. van den, Beijnen, J. H., \u2026 Jorritsma, A. (2014). Manufacture of gene-modified human T-cells with a memory stem\/central memory phenotype. Human Gene Therapy Methods, 25(5), 277\u2013287. https:\/\/doi.org\/10.1089\/hgtb.2014.004","DOI":"10.1089\/hgtb.2014.004"},{"key":"10228_CR69","doi-asserted-by":"publisher","unstructured":"Shah, N. N., Zurko, J., Fenske, T. S., Hamadani, M., Schneider, D., Xu, H., \u2026 Hari, P. (2021). Clinical and manufacturing outcomes of LV20.19 CAR T-cells expanded in IL-2 versus IL-7 and IL-15. Transplantation and Cellular Therapy, 27(3), S194\u2013S195. https:\/\/doi.org\/10.1016\/s2666-6367(21)00240-2","DOI":"10.1016\/s2666-6367(21)00240-2"},{"issue":"2","key":"10228_CR70","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1182\/bloodadvances.2023010607","volume":"8","author":"S-Y Wang","year":"2024","unstructured":"Wang, S.-Y., Scurti, G. M., Dalheim, A. V., Quinn, S., Stiff, P. J., & Nishimura, M. I. (2024). Nonactivated and IL-7 cultured CD19-specific CAR T cells are enriched in stem cell phenotypes and functionally superior. Blood Advances, 8(2), 324\u2013335. https:\/\/doi.org\/10.1182\/bloodadvances.2023010607","journal-title":"Blood Advances"},{"key":"10228_CR71","doi-asserted-by":"publisher","unstructured":"Alizadeh, D., Wong, R. A., Yang, X., Wang, D., Pecoraro, J. R., Kuo, C.-F., \u2026 Brown, C. E. (2019). IL-15-mediated reduction of mTORC1 activity preserves the stem cell memory phenotype of CAR-T cells and confers superior antitumor activity. Cancer Immunology Research, 7(5), canimm.0466.2018. https:\/\/doi.org\/10.1158\/2326-6066.cir-18-0466","DOI":"10.1158\/2326-6066.cir-18-0466"},{"key":"10228_CR72","doi-asserted-by":"publisher","unstructured":"Zurko, J., Xu, H., Chaney, K., Fenske, T., Hamadani, M., Schneider, D., \u2026 Shah, N. (2021). 8-day versus 12-day manufacturing of LV20.19 CAR T-cells impacts single cell cytokine profiles without increasing severity of toxicities. Cytotherapy, 23(5), S89. https:\/\/doi.org\/10.1016\/s1465324921004060","DOI":"10.1016\/s1465324921004060"},{"key":"10228_CR73","doi-asserted-by":"publisher","unstructured":"Klebanoff, C. A., Crompton, J. G., Leonardi, A. J., Yamamoto, T. N., Chandran, S. S., Eil, R. L., \u2026 Restifo, N. P. (2017). Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. JCI Insight, 2(23), e95103. https:\/\/doi.org\/10.1172\/jci.insight.95103","DOI":"10.1172\/jci.insight.95103"},{"key":"10228_CR74","doi-asserted-by":"publisher","unstructured":"Tang, J., Sheng, J., Zhang, Q., Ji, Y., Wang, X., Zhang, J., \u2026 Liang, T. (2023). Runx3-overexpression cooperates with ex vivo AKT inhibition to generate receptor-engineered T cells with better persistence, tumor-residency, and antitumor ability. Journal for ImmunoTherapy of Cancer, 11(2), e006119. https:\/\/doi.org\/10.1136\/jitc-2022-006119","DOI":"10.1136\/jitc-2022-006119"},{"issue":"3","key":"10228_CR75","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.immuni.2012.01.015","volume":"36","author":"RR Rao","year":"2012","unstructured":"Rao, R. R., Li, Q., Bupp, M. R. G., & Shrikant, P. A. (2012). Transcription factor Foxo1 represses T-bet-mediated effector functions and promotes memory CD8+ T cell differentiation. Immunity, 36(3), 374\u2013387. https:\/\/doi.org\/10.1016\/j.immuni.2012.01.015","journal-title":"Immunity"},{"issue":"2","key":"10228_CR76","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.immuni.2013.07.013","volume":"39","author":"MV Kim","year":"2013","unstructured":"Kim, M. V., Ouyang, W., Liao, W., Zhang, M. Q., & Li, M. O. (2013). The transcription factor Foxo1 controls central-memory CD8+ T cell responses to infection. Immunity, 39(2), 286\u2013297. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.013","journal-title":"Immunity"},{"issue":"6","key":"10228_CR77","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1084\/jem.20130392","volume":"210","author":"RH Michelini","year":"2013","unstructured":"Michelini, R. H., Doedens, A. L., Goldrath, A. W., & Hedrick, S. M. (2013). Differentiation of CD8 memory T cells depends on Foxo1. Journal of Experimental Medicine, 210(6), 1189\u20131200. https:\/\/doi.org\/10.1084\/jem.20130392","journal-title":"Journal of Experimental Medicine"},{"issue":"51","key":"10228_CR78","doi-asserted-by":"publisher","first-page":"7328","DOI":"10.1038\/sj.onc.1203159","volume":"18","author":"L del Peso","year":"1999","unstructured":"del Peso, L., Gonz\u00e1lez, V. M., Hern\u00e1ndez, R., Barr, F. G., & N\u00fa\u00f1ez, G. (1999). Regulation of the forkhead transcription factor FKHR, but not the PAX3-FKHR fusion protein, by the serine\/threonine kinase Akt. Oncogene, 18(51), 7328\u20137333. https:\/\/doi.org\/10.1038\/sj.onc.1203159","journal-title":"Oncogene"},{"key":"10228_CR79","doi-asserted-by":"publisher","unstructured":"Mackall, C., Doan, A., Mueller, K., Chen, A., Rouin, G., Daniel, B., \u2026 Weber, E. (2023). FOXO1 is a master regulator of CAR T memory programming. Research Square, rs.3.rs-2802998. https:\/\/doi.org\/10.21203\/rs.3.rs-2802998\/v1","DOI":"10.21203\/rs.3.rs-2802998\/v1"},{"key":"10228_CR80","doi-asserted-by":"publisher","unstructured":"Dwyer, C. J., Arhontoulis, D. C., Rivera, G. O. R., Knochelmann, H. M., Smith, A. S., Wyatt, M. M., \u2026 Paulos, C. M. (2020). Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8+ T cells. European Journal of Immunology, 50(9), 1386\u20131399. https:\/\/doi.org\/10.1002\/eji.201948455","DOI":"10.1002\/eji.201948455"},{"key":"10228_CR81","doi-asserted-by":"publisher","unstructured":"Mousset, C. M., Hobo, W., Ligt, A. de, Baardman, S., Schaap, N. P. M., Jansen, J. H., \u2026 Dolstra, H. (2020). Cell composition and expansion strategy can reduce the beneficial effect of AKT-inhibition on functionality of CD8+ T cells. Cancer Immunology, Immunotherapy, 69(11), 2259\u20132273. https:\/\/doi.org\/10.1007\/s00262-020-02612-w","DOI":"10.1007\/s00262-020-02612-w"},{"key":"10228_CR82","doi-asserted-by":"publisher","unstructured":"Bai, Y., He, T., Zhang, L., Liu, Q., Yang, J., Zhao, Z., \u2026 Zhang, M. (2022). Prognostic value of FOXP3+ regulatory T cells in patients with diffuse large B-cell lymphoma: A systematic review and meta-analysis. BMJ Open, 12(9), e060659. https:\/\/doi.org\/10.1136\/bmjopen-2021-060659","DOI":"10.1136\/bmjopen-2021-060659"},{"key":"10228_CR83","doi-asserted-by":"publisher","unstructured":"Good, Z., Spiegel, J. Y., Sahaf, B., Malipatlolla, M. B., Ehlinger, Z. J., Kurra, S., \u2026 Mackall, C. L. (2022). Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy. Nature Medicine, 28(9), 1860\u20131871. https:\/\/doi.org\/10.1038\/s41591-022-01960-7","DOI":"10.1038\/s41591-022-01960-7"},{"key":"10228_CR84","doi-asserted-by":"publisher","unstructured":"Voltin, C.-A., G\u00f6del, P., Beckmann, L., Heger, J.-M., Kobe, C., Kutsch, N., \u2026 Hanoun, C. (2023). Outcome prediction in patients with large B-cell lymphoma undergoing chimeric antigen receptor T-cell therapy. HemaSphere, 7(1), e817. https:\/\/doi.org\/10.1097\/hs9.0000000000000817","DOI":"10.1097\/hs9.0000000000000817"},{"key":"10228_CR85","doi-asserted-by":"publisher","unstructured":"Vercellino, L., Blasi, R. D., Kanoun, S., Tessoulin, B., Rossi, C., D\u2019Aveni-Piney, M., \u2026 Thieblemont, C. (2020). Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Advances, 4(22), 5607\u20135615. https:\/\/doi.org\/10.1182\/bloodadvances.2020003001","DOI":"10.1182\/bloodadvances.2020003001"},{"key":"10228_CR86","doi-asserted-by":"publisher","unstructured":"Blumenberg, V., Busch, G., Baumann, S., Jitschin, R., Iacoboni, G., Gallur, L., \u2026 Subklewe, M. (2023). Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R\/R DLBCL. Blood Advances, 7(22), 6844\u20136849. https:\/\/doi.org\/10.1182\/bloodadvances.2023010364","DOI":"10.1182\/bloodadvances.2023010364"},{"key":"10228_CR87","doi-asserted-by":"publisher","unstructured":"Nastoupil, L. J., Jain, M. D., Feng, L., Spiegel, J. Y., Ghobadi, A., Lin, Y., \u2026 Locke, F. L. (2020). Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: Results from the US lymphoma CAR T Consortium. Journal of Clinical Oncology, 38(27), 3119\u20133128. https:\/\/doi.org\/10.1200\/jco.19.02104","DOI":"10.1200\/jco.19.02104"},{"key":"10228_CR88","doi-asserted-by":"publisher","unstructured":"Rabinovich, E., Pradhan, K., Sica, R. A., Bachier-Rodriguez, L., Mantzaris, I., Kornblum, N., \u2026 Braunschweig, I. (2021). Elevated LDH greater than 400 U\/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort. Experimental Hematology & Oncology, 10(1), 55. https:\/\/doi.org\/10.1186\/s40164-021-00248-9","DOI":"10.1186\/s40164-021-00248-9"},{"key":"10228_CR89","doi-asserted-by":"publisher","unstructured":"Sworder, B. J., Kurtz, D. M., Alig, S. K., Frank, M. J., Shukla, N., Garofalo, A., \u2026 Alizadeh, A. A. (2023). Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell, 41(1), 210\u2013225.e5. https:\/\/doi.org\/10.1016\/j.ccell.2022.12.005","DOI":"10.1016\/j.ccell.2022.12.005"},{"key":"10228_CR90","doi-asserted-by":"publisher","unstructured":"Jain, M. D., Zhao, H., Wang, X., Atkins, R., Menges, M., Reid, K., \u2026 Locke, F. L. (2021). Tumor interferon signaling and suppressive myeloid cells associate with CAR T cell failure in large B cell lymphoma. Blood, 137(19), 2621\u20132633. https:\/\/doi.org\/10.1182\/blood.2020007445","DOI":"10.1182\/blood.2020007445"},{"key":"10228_CR91","doi-asserted-by":"publisher","unstructured":"Scholler, N., Perbost, R., Locke, F. L., Jain, M. D., Turcan, S., Danan, C., \u2026 Galon, J. (2022). Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nature Medicine, 28(9), 1872\u20131882. https:\/\/doi.org\/10.1038\/s41591-022-01916-x","DOI":"10.1038\/s41591-022-01916-x"},{"key":"10228_CR92","doi-asserted-by":"publisher","unstructured":"Grupp, S. A., Maude, S. L., Shaw, P., Aplenc, R., Barrett, D. M., Callahan, C., \u2026 June, C. H. (2014). T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) have long term persistence and induce durable remissions in children with relapsed, refractory ALL. Blood, 124(21), 380. https:\/\/doi.org\/10.1182\/blood.v124.21.380.380","DOI":"10.1182\/blood.v124.21.380.380"},{"key":"10228_CR93","doi-asserted-by":"publisher","unstructured":"Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., \u2026 Mackall, C. L. (2015). T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. The Lancet, 385(9967), 517\u2013528. https:\/\/doi.org\/10.1016\/s0140-6736(14)61403-3","DOI":"10.1016\/s0140-6736(14)61403-3"},{"key":"10228_CR94","doi-asserted-by":"publisher","unstructured":"Park, J. H., Riviere, I., Wang, X., Bernal, Y., Purdon, T., Halton, E., \u2026 Brentjens, R. J. (2015). Efficacy and safety of CD19-targeted 19\u201328z CAR modified T cells in adult patients with relapsed or refractory B-ALL. Journal of Clinical Oncology, 33(15_suppl), 7010\u20137010. https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.7010","DOI":"10.1200\/jco.2015.33.15_suppl.7010"},{"key":"10228_CR95","doi-asserted-by":"publisher","unstructured":"Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., \u2026 Grupp, S. A. (2018). Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. The New England Journal of Medicine, 378(5), 439\u2013448. https:\/\/doi.org\/10.1056\/nejmoa1709866","DOI":"10.1056\/nejmoa1709866"},{"key":"10228_CR96","doi-asserted-by":"publisher","unstructured":"Park, J. H., Rivi\u00e8re, I., Gonen, M., Wang, X., S\u00e9n\u00e9chal, B., Curran, K. J., \u2026 Sadelain, M. (2018). Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. The New England Journal of Medicine, 378(5), 449\u2013459. https:\/\/doi.org\/10.1056\/nejmoa1709919","DOI":"10.1056\/nejmoa1709919"},{"issue":"5","key":"10228_CR97","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1182\/bloodadvances.2020003482","volume":"6","author":"P Grover","year":"2021","unstructured":"Grover, P., Veilleux, O., Tian, L., Sun, R., Previtera, M., Curran, E., & Muffly, L. (2021). Chimeric antigen receptor-T cell therapy in adults with B-cell acute lymphoblastic leukemia: A systematic review. Blood Advances, 6(5), 1608\u20131618. https:\/\/doi.org\/10.1182\/bloodadvances.2020003482","journal-title":"Blood Advances"},{"key":"10228_CR98","doi-asserted-by":"publisher","unstructured":"Plaks, V., Rossi, J. M., Chou, J., Wang, L., Poddar, S., Han, G., \u2026 Neelapu, S. S. (2021). CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood, 138(12), 1081\u20131085. https:\/\/doi.org\/10.1182\/blood.2021010930","DOI":"10.1182\/blood.2021010930"},{"key":"10228_CR99","doi-asserted-by":"publisher","unstructured":"Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D., Wu, G., \u2026 Thomas-Tikhonenko, A. (2015). Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discovery, 5(12), 1282\u20131295. https:\/\/doi.org\/10.1158\/2159-8290.cd-15-1020","DOI":"10.1158\/2159-8290.cd-15-1020"},{"key":"10228_CR100","doi-asserted-by":"publisher","unstructured":"Orlando, E. J., Han, X., Tribouley, C., Wood, P. A., Leary, R. J., Riester, M., \u2026 Winckler, W. (2018). Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nature Medicine, 24(10), 1504\u20131506. https:\/\/doi.org\/10.1038\/s41591-018-0146-z","DOI":"10.1038\/s41591-018-0146-z"},{"key":"10228_CR101","doi-asserted-by":"publisher","unstructured":"Gardner, R., Wu, D., Cherian, S., Fang, M., Hanafi, L.-A., Finney, O., \u2026 Turtle, C. J. (2016). Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood, 127(20), 2406\u20132410. https:\/\/doi.org\/10.1182\/blood-2015-08-665547","DOI":"10.1182\/blood-2015-08-665547"},{"key":"10228_CR102","doi-asserted-by":"publisher","unstructured":"Ledererova, A., Dostalova, L., Kozlova, V., Peschelova, H., Ladungova, A., Culen, M., \u2026 Mancikova, V. (2021). Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro. Journal for ImmunoTherapy of Cancer, 9(8), e002352. https:\/\/doi.org\/10.1136\/jitc-2021-002352","DOI":"10.1136\/jitc-2021-002352"},{"key":"10228_CR103","doi-asserted-by":"publisher","unstructured":"Hamieh, M., Dobrin, A., Cabriolu, A., Stegen, S. J. C. van der, Giavridis, T., Mansilla-Soto, J., \u2026 Sadelain, M. (2019). CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature, 568(7750), 112\u2013116. https:\/\/doi.org\/10.1038\/s41586-019-1054-1","DOI":"10.1038\/s41586-019-1054-1"},{"key":"10228_CR104","doi-asserted-by":"publisher","first-page":"1178403","DOI":"10.3389\/fimmu.2023.1178403","volume":"14","author":"NJ Fergusson","year":"2023","unstructured":"Fergusson, N. J., Adeel, K., Kekre, N., Atkins, H., & Hay, K. A. (2023). A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells. Frontiers in Immunology, 14, 1178403. https:\/\/doi.org\/10.3389\/fimmu.2023.1178403","journal-title":"Frontiers in Immunology"},{"key":"10228_CR105","doi-asserted-by":"publisher","unstructured":"Li, S., Xue, L., Wang, M., Qiang, P., Xu, H., Zhang, X., \u2026 Wang, X. (2019). Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma. OncoTargets and therapy, 12, 5627\u20135638. https:\/\/doi.org\/10.2147\/ott.s198567","DOI":"10.2147\/ott.s198567"},{"issue":"8","key":"10228_CR106","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1080\/14712598.2022.2086043","volume":"22","author":"F Furqan","year":"2022","unstructured":"Furqan, F., & Shah, N. N. (2022). Bispecific CAR T-cells for B-cell malignancies. Expert Opinion on Biological Therapy, 22(8), 1005\u20131015. https:\/\/doi.org\/10.1080\/14712598.2022.2086043","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"1","key":"10228_CR107","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1146\/annurev-med-042921-024719","volume":"74","author":"F Furqan","year":"2022","unstructured":"Furqan, F., & Shah, N. N. (2022). Multispecific CAR T cells deprive lymphomas of escape via antigen loss. Annual Review of Medicine, 74(1), 279\u2013291. https:\/\/doi.org\/10.1146\/annurev-med-042921-024719","journal-title":"Annual Review of Medicine"},{"key":"10228_CR108","doi-asserted-by":"publisher","unstructured":"Zurko, J. C., Fenske, T. S., Johnson, B. D., Bucklan, D., Szabo, A., Xu, H., \u2026 Shah, N. N. (2022). Long\u2010term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T\u2010cells. American Journal of Hematology, 97(12), 1580\u20131588. https:\/\/doi.org\/10.1002\/ajh.26718","DOI":"10.1002\/ajh.26718"},{"key":"10228_CR109","doi-asserted-by":"publisher","unstructured":"Chapuy, B., Stewart, C., Dunford, A. J., Kim, J., Kamburov, A., Redd, R. A., \u2026 Shipp, M. A. (2018). Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nature Medicine, 24(5), 679\u2013690. https:\/\/doi.org\/10.1038\/s41591-018-0016-8","DOI":"10.1038\/s41591-018-0016-8"},{"issue":"12","key":"10228_CR110","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1182\/blood-2018-02-791350","volume":"132","author":"R Valentin","year":"2018","unstructured":"Valentin, R., Grabow, S., & Davids, M. S. (2018). The rise of apoptosis: Targeting apoptosis in hematologic malignancies. Blood, 132(12), 1248\u20131264. https:\/\/doi.org\/10.1182\/blood-2018-02-791350","journal-title":"Blood"},{"key":"10228_CR111","doi-asserted-by":"publisher","unstructured":"Gr\u00f8nb\u00e6k, K., Straten, P. thor, Ralfkiaer, E., Ahrenkiel, V., Andersen, M. K., Hansen, N. E., \u2026 Guldberg, P. (1998). Somatic Fas mutations in non-Hodgkin\u2019s lymphoma: Association with extranodal disease and autoimmunity. Blood, 92(9), 3018\u20133024https:\/\/doi.org\/10.1182\/blood.v92.9.3018","DOI":"10.1182\/blood.v92.9.3018"},{"key":"10228_CR112","doi-asserted-by":"publisher","unstructured":"Upadhyay, R., Boiarsky, J. A., Pantsulaia, G., Svensson-Arvelund, J., Lin, M. J., Wroblewska, A., \u2026 Brody, J. D. (2021). A critical role for Fas-mediated off-target tumor killing in T-cell immunotherapy. Cancer Discovery, 11(3), 599\u2013613. https:\/\/doi.org\/10.1158\/2159-8290.cd-20-0756","DOI":"10.1158\/2159-8290.cd-20-0756"},{"key":"10228_CR113","doi-asserted-by":"publisher","unstructured":"Cherng, H.-J. J., Sun, R., Sugg, B., Irwin, R., Yang, H., Le, C. C., \u2026 Westin, J. R. (2022). Risk assessment with low pass whole genome sequencing of cell free DNA before CD19 CAR T-cells for large B-cell lymphoma. Blood, 140(5), 504\u2013515. https:\/\/doi.org\/10.1182\/blood.2022015601","DOI":"10.1182\/blood.2022015601"},{"key":"10228_CR114","doi-asserted-by":"publisher","unstructured":"Dufva, O., Koski, J., Maliniemi, P., Ianevski, A., Klievink, J., Leitner, J., \u2026 Mustjoki, S. (2020). Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. Blood, 135(9), 597\u2013609. https:\/\/doi.org\/10.1182\/blood.2019002121","DOI":"10.1182\/blood.2019002121"},{"key":"10228_CR115","doi-asserted-by":"publisher","unstructured":"Lee, Y. G., Guruprasad, P., Ghilardi, G., Pajarillo, R., Sauter, C. T., Patel, R., \u2026 Ruella, M. (2022). Modulation of BCL-2 in both T cells and tumor cells to enhance chimeric antigen receptor T-cell immunotherapy against cancer. Cancer Discovery, 12(10), OF1\u2013OF20. https:\/\/doi.org\/10.1158\/2159-8290.cd-21-1026","DOI":"10.1158\/2159-8290.cd-21-1026"},{"key":"10228_CR116","doi-asserted-by":"publisher","unstructured":"Mandeville, T. K., Mavis, C., Gu, J., Bowman, K., Olejniczak, S., Dey, P., \u2026 Hernandez-Ilizaliturri, F. J. (2023). Mitochondrial reprogramming by Bcl-2 inhibitor venetoclax enhances \u03b1CD19 CAR-T cell fitness and anti-tumor efficacy. Blood, 142(Supplement 1), 6845. https:\/\/doi.org\/10.1182\/blood-2023-191051","DOI":"10.1182\/blood-2023-191051"},{"key":"10228_CR117","unstructured":"CD19CD22 CAR-T therapy in patients with high-risk B acute lymphoblastic leukemia (B-ALL). (n.d.). NCT06078306. webpage."},{"key":"10228_CR118","doi-asserted-by":"publisher","unstructured":"Shouval, R., Tomas, A. A., Fein, J. A., Flynn, J. R., Markovits, E., Mayer, S., \u2026 Palomba, M. L. (2022). Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy. Journal of Clinical Oncology, 40(4), 369\u2013381. https:\/\/doi.org\/10.1200\/jco.21.02143","DOI":"10.1200\/jco.21.02143"},{"key":"10228_CR119","doi-asserted-by":"publisher","unstructured":"Jain, M. D., Ziccheddu, B., Coughlin, C. A., Faramand, R., Griswold, A. J., Reid, K. M., \u2026 Maura, F. (2022). Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood, 140(5), 491\u2013503. https:\/\/doi.org\/10.1182\/blood.2021015008","DOI":"10.1182\/blood.2021015008"},{"key":"10228_CR120","doi-asserted-by":"publisher","unstructured":"Yan, X., Chen, D., Ma, X., Wang, Y., Guo, Y., Wei, J., \u2026 Han, W. (2022). CD58 loss in tumor cells confers functional impairment of CAR T cells. Blood Advances, 6(22), 5844\u20135856. https:\/\/doi.org\/10.1182\/bloodadvances.2022007891","DOI":"10.1182\/bloodadvances.2022007891"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-024-10228-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-024-10228-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-024-10228-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T02:58:26Z","timestamp":1743303506000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-024-10228-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":120,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10228"],"URL":"https:\/\/doi.org\/10.1007\/s10555-024-10228-0","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,1]]},"assertion":[{"value":"12 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Shah has reported consulting with multiple CAR-T companies as outlined in the disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"12"}}